ReviewVirulence2017
The microbiome-metabolome crosstalk in the pathogenesis of respiratory fungal diseases.
Review in Virulence, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Article
- Pulmonary Drug Delivery for Infectious Diseases: Cutting-Edge Formulations and Manufacturing Technologies.Pharmaceutics · 2026Review
- Review
- Pathogenicity and virulence ofVirulence · 2023Review
- Genome-scale metabolic modeling of Aspergillus fumigatus strains reveals growth dependencies on the lung microbiome.Nature communications · 2023Article
- Assessment of the nasal microbiota in dogs with fungal rhinitis before and after cure and in dogs with chronic idiopathic rhinitis.BMC microbiology · 2023Article
- Lung microbiota predict invasive pulmonary aspergillosis and its outcome in immunocompromised patients.Thorax · 2022Observational
- Future Directions for Clinical Respiratory Fungal Research.Mycopathologia · 2021Review
- A Shifted Composition of the Lung Microbiota Conditions the Antifungal Response of Immunodeficient Mice.International journal of molecular sciences · 2021Article
- Use of Integrative Interactomics for Improvement of Farm Animal Health and Welfare: An Example with Fescue Toxicosis.Toxins · 2020Review
- Interactions between invasive fungi and symbiotic bacteria.World journal of microbiology & biotechnology · 2020Review
- Gut Microbiota Abrogates Anti-α-Gal IgA Response in Lungs and Protects against ExperimentalVaccines · 2020Article
- Insights into the role of intestinal microbiota in hematopoietic stem-cell transplantation.Therapeutic advances in hematology · 2020Review
- Grand Challenges in the Research of Fungal Interactions With Animals.Frontiers in fungal biology · 2020Article
- Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy.Frontiers in oncology · 2020Review
- Aspergillus fumigatus and Aspergillosis in 2019.Clinical microbiology reviews · 2019Review
- Dendritic cells trigger imbalance of Th1/Th2 cells in silica dust exposure rat modelRSC advances · 2018Article
- Early and Non-invasive Diagnosis of Aspergillosis Revealed by Infection Kinetics Monitored in a Rat Model.Frontiers in microbiology · 2018Article
- The lung microbiome in patients with pneumocystosis.BMC pulmonary medicine · 2017Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Filamentous fungi of the genus Aspergillus are responsible for several superficial and invasive infections and allergic syndromes. The risk of infection and its clinical outcome vary significantly even among patients with similar predisposing clinical factors and pathogen exposure. There is increasing evidence that the individual microbiome supervises the outcome of the host-fungus interaction by influencing mechanisms of immune regulation, inflammation, metabolism, and other physiological processes. Microbiome-mediated mechanisms of resistance allow therefore the control of fungal colonization, preventing the onset of overt disease, particularly in patients with underlying immune dysfunction. Here, we review this emerging area of research and discuss the contribution of the microbiota (and its dysbiosis), including its immunoregulatory properties and relationship with the metabolic activity of commensals, to respiratory fungal diseases. Finally, we highlight possible strategies aimed at decoding the microbiome-metabolome dialog and at its exploitation toward personalized medical interventions in patients at high risk of infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.